Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

@article{Stephens2007EpidemicMM,
  title={Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
},
  author={David S. Stephens and Brian Greenwood and Petter Brandtzaeg},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={2196-2210}
}
Meningococcus, an obligate human bacterial pathogen, remains a worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal… Expand

Paper Mentions

Interventional Clinical Trial
This study will be a randomized observer -blinded controlled non-inferiority study to evaluate and compare the immunogenicity of locally produced Ingovax ACWY with Quadri Meningo… Expand
ConditionsMeningococcal Vaccine
InterventionBiological
Invasive Meningococcal Disease in the 21st Century—An Update for the Clinician
TLDR
This review covers key aspects of the pathogenesis and management of meningitis or bacteremia, as well as the very recent developments in disease epidemiology, outbreaks, and the evolution ofMeningococcal immunizations. Expand
Neisseria meningitidis infection: who, when and where?
TLDR
Although a reduction in meningitis disease has been observed in Europe, a continuous surveillance is necessary to control any possible outbreaks of new hypervirulent clones into populations that could modify the epidemiology of meningococcal infections and the clinical spectrum of affected subjects. Expand
Neisseria meningitidis B vaccines
TLDR
The aims of this article are to describe the most recent developments in meningitis B vaccines and to discuss how these vaccines can contribute to containing meningococcal disease. Expand
Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.
TLDR
The general status of knowledge of pathogenesis of meningococcal carriage, transmission and virulence behavior is reviewed with particular emphasis on the relevance of research on this topic to vaccine development. Expand
Neisseria meningitidis: a silent killer?
TLDR
This review provides information about the morphology, cultivation, taxonomy, pathogenesis, clinical manifestations, laboratory diagnosis and therapy for Neisseria meningitidis. Expand
Impact of vaccination on meningococcal epidemiology
TLDR
Large-scale vaccination campaigns with the MCC vaccine and with MenAfriVac in the Sahel have clearly demonstrated the direct and indirect effect of immunization programmes on disease and carriage, and the introduction of novel subcapsular vaccines against serogroup B, which may cross-protect against other serogroups, is likely to have a further effect on trends. Expand
Invasive Meningococcal Disease in the Vaccine Era
TLDR
This review summarizes clinical features of IMD and current treatment recommendations and will discuss the evidence for immunization and effects of vaccine strategies, particularly following implementation of effective vaccines against Group B meningococcus. Expand
Mechanisms of meningococcal colonisation.
TLDR
Understanding the mechanisms that enable neisserial colonisation, in terms of the role of type IV pili, the impact of other adhesins, biofilm formation, nutrient acquisition and resistance to host immune defences, will lead to more effective vaccines and therapeutic strategies. Expand
Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease.
  • D. Caugant
  • Biology, Medicine
  • Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2008
TLDR
This review addresses some of the impacts of the evolutionary potential of N. meningitidis on the occurrence of meningococcal disease. Expand
Meningococcal disease serogroup C
TLDR
A combination of all of the aforementioned approaches is useful in the prevention and control of MDC, and each country should tailor its public health policy to its own particular needs and knowledge of disease burden. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 209 REFERENCES
Epidemiology and pathogenesis of Neisseria meningitidis.
TLDR
Current knowledge of the human susceptibility to and the epidemiology and molecular pathogenesis of meningitis and meningococcal disease is summarized. Expand
Serogroup B meningococcal vaccines.
TLDR
Progress toward an effective serogroup B vaccine, an important addition for meningococcal disease prevention, is the focus of this review. Expand
Update on meningococcal disease with emphasis on pathogenesis and clinical management.
TLDR
The overall mortality rate of meningococcal disease can only be reduced when patients without meningitis, i.e., those who may develop FMS, are recognized early, and the fundamental nature of the disease as aMeningococcus septicemia deserves more attention. Expand
Population genetics and molecular epidemiology of Neisseria meningitidis
  • D. Caugant
  • Biology, Medicine
  • APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • 1998
TLDR
The characteristics of the predominant clones which are nowadays causing meningococcal disease in the world are summarized here and the importance of population genetics in interpreting the epidemiological data is illustrated. Expand
Meningococcal carriage and disease—Population biology and evolution
TLDR
The application of insights gained from studies of meningococcal population biology and evolution is important in understanding the spread of disease, as well as in vaccine development and implementation, especially with regard to the challenge of producing comprehensive vaccines based on sub-capsular antigens and measuring their effectiveness. Expand
A universal vaccine for serogroup B meningococcus.
TLDR
The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity and has the potential to conquer one of the most devastating diseases of childhood. Expand
Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process.
  • P. Moore
  • Biology, Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1992
TLDR
Despite the unique behavior of group A meningococcal disease in sub-Saharan Africa, the application of similar methods of epidemiological analysis may be useful for determining epidemic processes for other diseases. Expand
Manson Lecture. Meningococcal meningitis in Africa.
  • B. Greenwood
  • Medicine
  • Transactions of the Royal Society of Tropical Medicine and Hygiene
  • 1999
TLDR
In the medium term, the best prospect for the control of meningococcal meningitis in Africa lies in the recent development of polysaccharide-protein conjugate vaccines which, unlike poly Saccharide vaccines, are immunogenic in the very young, induce immunological memory and are likely to give long-lasting protection. Expand
Neisseria meningitidis: an overview of the carriage state.
TLDR
The high diversity of meningococcal carrier strains, compared with hypervirulent strains, supports the idea that transmissibility, not invasion, is essential in the life cycle of N. meningitidis. Expand
Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns.
TLDR
In France, during 1999-2002, a total of 2167 clinical isolates of N. meningitidis from invasive infections were studied, and strains were heterogeneous and accounted for approximately 30% of isolates during this period, warranting continued surveillance of this phenomenon. Expand
...
1
2
3
4
5
...